Skip to content

Analysis of archived database to check correlation between CANscript test results and actual clinical outcome in cancer subjects

Retrospective database analysis study to assess the predictive power of CANscriptTM in solid cancers - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/12/010730
Enrollment
1750
Registered
2017-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms Health Condition 2: null- Solid cancer

Interventions

None listed

Sponsors

Mitra RxDx India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 CANscript test report for solid cancers such as head and neck colorectal gastrointestinal breast ovary lung etc 2 CANscript results with M-score available for at least 1 tested arm 3 Availability of clinical outcome data in terms of tumor responses for respective CANscript tested

Exclusion criteria

Exclusion criteria: (1) No specific exclusion criteria can be defined for the retrospective analysis

Design outcomes

Primary

MeasureTime frame
1. Positive and negative prediction rate in overall and each cancer type population 2. Percentage of correctly identified clinical responder and nonresponders, in overall and each cancer type populationTimepoint: [6 weeks]

Secondary

MeasureTime frame
Compare positive, negative predictive values, sensitivity and specificity, in overall and each cancer type population using cohort as cytotoxic and cytostatic class of anti-cancer drugsTimepoint: [6 weeks];Sensitivity and specificity rate in overall and each cancer type populationTimepoint: [6 weeks];Summarize demographics (male, female, age, etc), cancer type and stages, drugs tested â?? alone, combinations, classes as chemotherapy, targeted (small molecules, biologicals, etc) and cytotoxic / cytostatic drugsTimepoint: [6 weeks]

Countries

India

Contacts

Public ContactDr Rahul Rathod

Mitra RxDx India Pvt. Ltd

rahul.rathod@mitrabiotech.com9987246597

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026